Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar tttchicattt (24.75) Submitted: 10/8/2010 2:25:40 AM : Underperform Start Price: $29.87 ACOR Score: +38.34

tspy rec

Featured Broker Partners


Advertisement